Navigation Links
Health Strategies Group Expands Focus of Pharma Sales Force Effectiveness Service Under New Vision and Name
Date:4/16/2009

Strategic Selling Outlook Addresses Rapidly Changing Selling Environment and Future Needs of Physicians and Sales Representatives

LAMBERTVILLE, N.J., April 16 /PRNewswire/ -- Health Strategies Group, a leading provider of market intelligence to the pharmaceutical and biotechnology industries, has realigned its pharmaceutical sales force effectiveness service under a more strategic, future-oriented business vision and renamed the group Strategic Selling Outlook. The goal of these changes is to help clients address the complex issues posed by today's selling environment and to anticipate and successfully navigate the selling environments of the future.

"The world is changing dramatically for those involved in pharmaceutical sales and the wisest course of action is to embrace that change and make use of the opportunities it presents," said Rick Rosenthal, a principal at Health Strategies Group and leader of the company's sales force effectiveness practice, which includes Strategic Selling Outlook as well as services geared to sales management and hospital sales force effectiveness.

"Information that is immediately actionable against a specific challenge is good, but today's selling environment requires information that helps pharmaceutical companies assess physician attitudes and prescribing behavior over time," he noted. "Strategically, it's critical to get ahead of emerging trends and uncover unmet needs and gaps in knowledge. Our goal with Strategic Selling Outlook is to provide both types of intelligence."

Through thousands of interviews and surveys, Strategic Selling Outlook gives pharmaceutical companies a complete picture of the selling environment for the upcoming year as well as scenarios looking five years into the future. Reflecting the perspectives of multiple stakeholders, each analysis looks at several key factors affecting sales and customer relationships, including how individual sales forces are rated, how their competitors compare, and personal traits and professional best-practices shared by effective sales representatives. The findings, coupled with counsel by HSG staff who are experts in sales force effectiveness, are used in planning sales strategies and developing sales training and coaching programs.

"We have to understand what doctors value and want in sales representatives today along with what they'll value and want tomorrow," Rosenthal said. "The physician's world has changed significantly in the past decade and will continue to change. To be effective, sales representatives must keep pace with this change and expand the scope of services they provide. Whether it's deeper knowledge about a specific side effect or guidance in navigating a particular managed care plan, sales representatives need to be trained to take a more customer-centric approach to selling that responds to the constantly evolving needs of physicians."

About Health Strategies Group

Health Strategies Group has been providing market intelligence to pharmaceutical and biotechnology professionals since 1992, transforming research findings into practical insights and strategic recommendations to help organizations make the best business decisions. The company has long-standing relationships with 90 percent of the nation's leading pharmaceutical and biotechnology companies.

Health Strategies Group services include syndicated research reports in different practice areas, proprietary intelligence projects on request, and direct, continuous access to a team of research directors and practice leaders who are experienced veterans of the pharmaceutical industry and active thought leaders in their areas of expertise. The company also creates a custom webpage for each client that provides ready access to all pertinent publications and research summaries.

Organizations use Health Strategies Group to assess marketplace trends and future scenarios, support business planning, formulate successful segmentation strategies, guide the design of training curricula, educate colleagues, benchmark staff performance, and develop more profitable contracting strategies.

For additional information on Health Strategies Group or Strategic Selling Outlook, contact Karen Vandeven, director of marketing and communications, at (609) 397-5282 or kvandeven@healthstrategies.com. Health Strategies Group is headquartered in Lambertville, N.J., with regional offices in Redwood City, Carlsbad and Irvine, Calif. Visit the company's Web site at www.HealthStrategies.com.

    CONTACT:  Julie Laitin (212) 286-2424      Cynthia Amorese (908) 665-8072
              Email: jlaitin@julielaitin.com   Email: camorese@comcast.net


'/>"/>
SOURCE Health Strategies Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. inVentiv Health to Announce First Quarter 2009 Results and Conduct Conference Call on Friday, May 8
2. Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay
3. Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008
4. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
5. Healthplace America Engages Robert A. Yungk to Provide Services as Chief Strategy Officer
6. Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide
7. MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care
8. Siemens Healthcare Announces Planned Collaboration with Harris Corporation
9. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
10. Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors
11. Health Care Innovations and Opportunities Attract Attendees from 40 Countries and Delegations from 12 to 6th Annual World Health Care Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017 Shareholder rights law firm ... whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... connection with the proposed sale of the Company to ... that develops small molecules for the acute treatment of ... it had signed a definitive merger agreement with Eli ...
(Date:1/18/2017)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF) ... and commercializes proprietary technologies and products for advanced ... that Cameron Prange , President of Kingsdale ... Board of Directors.  Mr. Prange,s resignation is related ... limited both his ability to act on behalf ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... Balance™ GT soybeans. The new Balance™ GT Soybean Performance System will combine industry-leading ... isoxaflutole, the active ingredient in the new Balance® Bean herbicide. The Balance™ GT ...
(Date:1/17/2017)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... detection of foodborne pathogens today announced the appointment of Mary ... Thomas , the Company,s President and CEO since 2009, who will ... The changes are effective today. In addition, Ms. Duseau ... ...
Breaking Biology Technology:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):